By targeting specific molecular pathways involved in cancer progression, such as PI3K/AKT/mTOR, Notch, and Wnt, and leveraging immune responses with checkpoint inhibitors like PD-1/PD-L1 and CTLA-4, these therapies can halt tumor growth, reduce recurrence, and improve patient outcomes (4). Here, CD274 is linked to neoplasm.